While the weight-loss peptide conversation in 2026 is largely dominated by GLP-1 and multi-receptor agonists, another class of peptides continues to command significant attention in metabolic research: Growth Hormone-Releasing Hormone (GHRH) analogs. Among these, **Tesamorelin** stands out as the most extensively researched and clinically validated compound for a very specific target: visceral adipose tissue (VAT). […]
